Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 17 January 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Chronic cough and gastroesophageal reflux disease

Researchers from Rochester, New York, find that 4 to 6 weeks of a proton-pump inhibitor successfully diagnoses and treats most patients with GERD-related cough.

News image

fiogf49gjkf04

In this study, researchers evaluated proton-pump inhibitor therapy, with or without a prokinetic agent, in the diagnosis and treatment of gastroesophageal reflux disease (GERD)-related cough.

The team performed a review of their experience of 214 patients with a cough of 3 weeks, referred over a 3 and a half year period.

The cough was eliminated or markedly improved in 86% of patients after 4 weeks.
Chest

Their findings are published in the March issue of Chest.

Overall, the team identified 183 patients with chronic cough, these were included in the study. However, 31 patients were disqualified because of abnormal chest radiographic findings, inadequate follow-up, or cough being not the primary complaint.

Of the 183 patients, 56 were identified as having GERD-related cough.

The team prescribed these patients a once-daily dose of a proton-pump inhibitor.

In addition, the team added a prokinetic agent if esophageal dysfunction was suspected, or response was inadequate.

Patients who did not respond underwent 24-hour esophageal pH monitoring.

The research team found that GERD was the single cause of cough in 43% of patients. A further 52% had GERD plus another cause, and 5% patients had GERD with more than 2 causes.

The team also determined that 43% of patients had a cough only, while 57% had other symptoms of GERD.

Overall, proton-pump therapy was successful in 79% of patients.

The team found that 24 patients responded to proton-pump inhibitor therapy, and 18 patients responded when metoclopramide or cisapride was added. The remaining 2 patients responded to a histamine type-2 blocker or cisapride alone.

The cough was eliminated or markedly improved in 86% of patients after 4 weeks, and by 8 weeks in the remaining 6 patients.

The team found that 6 of the nonresponders had aspiration diagnosed by bronchoscopy.

Additionally, 4 patients had fundoplication recommended, and 2 patients responded to alternative interventions.

Drs Robert Poe and Michael Kallay concluded, "4 to 6 weeks of a proton-pump inhibitor alone or in combination with a prokinetic agent successfully diagnoses and treats 4 of 5 patients with GERD-related cough".

"24-hour esophageal pH monitoring will confirm the diagnosis in the others."

"These patients may be candidates for fundoplication."

"Nonresponders often aspirate as an additional aggravating factor."

Chest 2003; 123: 679-84
14 March 2003

Go to top of page Email this page Email this page to a colleague

 17 January 2017 
Pediatric-onset Crohn's disease
 17 January 2017 
Biologic drugs and extraintestinal manifestations in IBD
 17 January 2017 
Colorectal cancer prevention among Medicare beneficiaries
 16 January 2017 
HCV eradication in cirrhosis
 16 January 2017 
Thyroid and primary biliary cholangitis
 16 January 2017 
Sarcopenia and severe liver fibrosis
 13 January 2017 
Early monocytopenia in paracetamol-induced liver failure
 13 January 2017 
Anti-TNF discontinuation in patients with IBD
 13 January 2017 
Isolated colonic Crohn's disease
 12 January 2017 
Providing relief for chronic constipation
 12 January 2017 
Internet-delivered therapy for adolescents with IBS
 12 January 2017 
NAFLD and coronary artery calcium score
 11 January 2017 
Fatigue in IBD
 11 January 2017 
Pancreatic cancer risk with asthma and nasal allergies
 11 January 2017 
PPIs and bone strength and structure
 10 January 2017 
Colorectal cancer risk in serrated polyposis syndrome
 10 January 2017 
Evaluation of abnormal liver chemistries
 10 January 2017 
Pelvic physiotherapy in functional constipation
 09 January 2017 
Intestinal microbiota and IBS
 09 January 2017 
Helicobacter and Campylobacter in IBD
 09 January 2017 
Diagnosis of microscopic colitis
 06 January 2017 
Recommendations on colorectal cancer screening 
 06 January 2017 
Colorectal cancer susceptibility gene variants
 06 January 2017 
Thiopurine-induced hepatotoxicity in IBD
 05 January 2017 
Histological index for ulcerative colitis
 05 January 2017 
Crohn's disease after total colectomy with permanent ileostomy
 05 January 2017 
Celiac disease screening in IBS
 04 January 2017 
Serrated colorectal polyps risk factors
 04 January 2017 
Score to predict eosinophilic esophagitis
 04 January 2017 
Platelet transfusion for gastrointestinal bleeding
 03 January 2017 
Pelvic physiotherapy for functional constipation in children
 03 January 2017 
Tumor necrosis factor antagonists in IBD
 03 January 2017 
Mesenchymal stromal cell therapy for IBD
 22 December 2016 
Happy holidays!
 21 December 2016 
Pharmacotherapy for NAFLD
 21 December 2016 
Predicting disease activity in eosinophilic esophagitis
 21 December 2016 
Breath Testing for Barrett’s esophagus
 20 December 2016 
H. pylori on the ethnic distribution of Barrett's metaplasia
 20 December 2016 
Prognostic biomarker in colorectal cancer
 20 December 2016 
Online health information for colorectal cancer screening
 19 December 2016 
Risk of tuberculosis in IBD
 19 December 2016 
Hospital research and colorectal cancer survival
 19 December 2016 
Risk of complications of percutaneous liver biopsy
 16 December 2016 
Mortality rates for major causes of death
 16 December 2016 
Predicting organ failure in acute pancreatitis
 16 December 2016 
Non-invasive genomic biomarkers for colorectal cancer
 15 December 2016 
Adjuvant chemotherapy use varies for advance colon cancer
 15 December 2016 
Histological index for ulcerative colitis
 15 December 2016 
Readmission after acute upper GI bleed
 14 December 2016 
Management of H. pylori infection
 14 December 2016 
Fecal microbiota transfer
 14 December 2016 
Colorectal cancer screening in primary care
 13 December 2016 
Caffeine and hepatitis C virus infection
 13 December 2016 
Features of asymptomatic erosive esophagitis
 13 December 2016 
Clinical relapse among patients with ulcerative colitis
 12 December 2016 
Colorectal cancer prevention
 12 December 2016 
Precision medicine in IBD
 12 December 2016 
Drug-induced liver injury 
 09 December 2016 
Use of GI alarm features for colorectal cancer diagnosis
 09 December 2016 
Emergency department use by IBD patients

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us